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Abstract
AIM
To evaluate the ability of Lactobacillus rhamnosus  
HN001 and Bifidobacterium longum BB536 to colonize 
the intestinal environment of healthy subjects and 
modify the gut microbiota composition.
METHODS
Twenty healthy Italian volunteers, eight males and 
twelve females, participated in the study. Ten subjects 
took a sachet containing 4 × 109 colony-forming units 
(CFU) of Bifidobacterium longum BB536 and 109 CFU 
of Lactobacillus rhamnosus  HN001, 30 min before 
breakfast (pre-prandial administration), while ten 
subjects took a sachet of probiotic product 30 min after 
breakfast (post-prandial administration). The ability of 
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Lactobacillus rhamnosus  HN001 and Bifidobacterium 
longum BB536 to colonize human gut microbiota was 
assessed by means of quantitative real-time PCR, while 
changes in gut microbiota composition were detected 
by using Ion Torrent Personal Genome Machine.
RESULTS
Immediately after 1-mo of probiotic administration, 
B. longum BB536 and L. rhamnosus  HN001 load was 
increased in the majority of subjects in both pre-
prandial and post-prandial groups. This increase was 
found also 1 mo after the end of probiotic oral intake in 
both groups, if compared to samples collected before 
probiotic consumption. At phyla level a significant 
decrease in Firmicutes  abundance was detected 
immediately after 1-mo of B. longum  BB536 and L. 
rhamnosus  HN001 oral intake. This reduction persisted 
up to 1 mo after the end of probiotic oral intake 
together with a significant decrease of Proteobacteria  
abundance if compared to samples collected before 
probiotic administration. Whereas, at species level, a 
higher abundance of Blautia producta , Blautia wexlerae  
and Haemophilus ducrey  was observed, together with a 
reduction of Holdemania filiformis , Escherichia vulneris , 
Gemmiger formicilis  and Streptococcus sinensis 
abundance. In addition, during follow-up period we 
observed a further reduction in Escherichia vulneris 
and Gemmiger formicilis , together with a decrease in 
Roseburia faecis  and Ruminococcus gnavus  abundance. 
Conversely, the abundance of Akkermansia muciniphila  
was increased if compared to samples collected at the 
beginning of the experimental time course
CONCLUSION
B. longum BB536 and L. rhamnosus  HN001 showed 
the ability to modulate the gut microbiota composition, 
leading to a significant reduction of potentially harmful 
bacteria and an increase of beneficial ones. Further 
studies are needed to better understand the specific 
mechanisms involved in gut microbiota modulation.
Key words: Probiotics; Gut microbiota; Bifidobacterium; 
Lactobacillus ; Human health
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Core tip: Several studies have described the potentially 
beneficial effects of many probiotic microorganisms 
belonging to Lactobacillus  and Bifidobacterium genera. 
We evaluated the ability of Bifidobacterium longum 
BB536 and Lactobacillus rhamnosus  HN001, two 
probiotic strains used in combination, to colonize the 
intestinal environment of healthy subjects and modify 
the gut microbiota composition. We did not observe 
a negative impact of probiotic on the general health 
status of the hosts. Contrariwise, the two bacterial 
strains seemed able to exert a beneficial effect on 
the bacterial ecology of the gastrointestinal tract, as 
many significant positive changes in gut microbiota 
composition have been highlighted.
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INTRODUCTION
Probiotics are defined as “non-pathogenic live micro-
organisms that, when administered in adequate 
amounts, confer a health benefit on the host”[1]. In 
the last years, their numerous beneficial properties 
and positive impact on human health have deeply 
been described[2]. Consequently, the global market for 
probiotics is growing due to the increased demand of 
consumers who use these products to improve their 
health and even to prevent some human illnesses 
such as allergic and gastrointestinal diseases, modu-
late immune system and ensure the homeostasis 
of intestinal microbiota[3-5]. Nowadays, hundreds of 
different bacterial strains are available in the global 
probiotic market and consequently, the choice of 
the most suitable probiotic product becomes very 
difficult and fragmented. For these reasons, safety and 
efficacy of probiotics are considered the main criteria 
for using any microorganism in the formulation of pro-
biotic products[6]. Lactobacilli and Bifidobacteria are 
the main microorganisms used as probiotics; indeed, 
numerous species belonging to these genera have 
been reported as safe and effective in improving the 
host’s health[7]. Interestingly, modulation of intestinal 
microbiota composition has been proposed as one of 
the main mechanisms of probiotic activity[8]. Several 
studies showed that the combination of specific 
bacterial strains belonging to Lactobacillus and Bifido­
bacterium species can act in optimal synergy for 
restoring the intestinal balance[9-11]. In 2015, Drago 
et al[12], for instance, highlighted the immunomodulatory 
synergy of L. salivarius LS01 and Bifidobacterium 
breve BR03 which combination led to an increased 
immunomodulatory activity if compared to the activity 
of each single strain. Also Bifidobacterium longum 
(B. longum) BB536 and Lactobacillus rhamnosus 
(L. rhamnosus) HN001 are two well-characterized 
probiotic strains often used in combination which ability 
to survive the adverse gastrointestinal conditions 
and adhere to intestinal mucosa has already been 
demonstrated in a previous study[13]. These probiotic 
strains possess strong immunomodulatory activities, 
are able to improve human health, reduce eczema 
prevalence in children and inhibit adhesion of gram-
negative pathogens in intestinal environment[14-21].
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The aim of the present study was to investigate the 
effects of B. longum BB536 and L. rhamnosus HN001 
on the gut microbiota composition of healthy subjects 
after one month of probiotic oral intake, also evaluating 
the potential impact of pre- and post-prandial probiotic 
administration on the colonization ability of B. longum 
BB536 and L. rhamnosus HN001. 
MATERIALS AND METHODS
Experimental design
Twenty healthy Italian subjects, eight males and 
twelve females, participated in the study. They were 
all volunteers who were informed in detail about the 
aim of the study. Baseline characteristics for each 
subject are summarized in Table 1. All individuals 
personally delivered fecal samples to the Laboratory of 
Clinical Microbiology (University of Milan, Milan). The 
experimental protocol was approved by the Scientific 
Direction of IRCCS Galeazzi Orthopaedic Institute in 
the Current Research 2015.
Exclusion criteria included antibiotic treatment 
within the previous 2 mo or suffering from any 
acute or chronic cardiovascular, gastrointestinal or 
immunological conditions. Furthermore, probiotics 
and yogurt have been excluded from the diet during 
the study period. Volunteers were randomized in two 
groups. The probiotic product was provided by Alfa 
Wassermann S.p.a. (Milan, Italy) that also supplied 
evidence about its safety for human consumption. 
Ten subjects took a sachet containing 4 × 109 colony-
forming units (CFU) of B. longum BB536 and 109 
colony-forming units (CFU) of L. rhamnosus HN001 
30 min before breakfast (pre-prandial administration), 
while ten subjects took a sachet of probiotic product 
30 min after breakfast (post-prandial administration). 
During the probiotic resuspension and before oral 
intake, some volunteers described the formation of 
lumps inside the solution. Moreover, the product was 
tasteless and odorless, favoring the daily oral intake. 
Fecal samples were collected from each participant 
one week before the probiotic oral intake, after one 
month of probiotic administration and one month 
after the end of probiotic consumption. Two subjects 
were excluded from the study following an antibiotic 
therapy, while 2 individuals were excluded from the 
data analysis as they did not strictly follow the diet. 
DNA extraction
Total DNA was extracted from fecal samples using the 
QIAamp DNA Stool Mini Kit following the manufacturer’s 
instructions (Qiagen, Italy). 
Quantitative PCR
The ability of B. longum BB536 and L. rhamnosus 
HN001 to colonize the human gut microbiota was 
assessed by means of a quantitative real-time PCR 
carried out using a Rotor Gene 3000 system (Diatech), 
in order to evaluate the potential increase of the 
lactobacilli and bifidobacteria load following the 
probiotic oral intake. For B. longum DNA amplification 
the following primers were used: B. longum (forward) 
5’-TTCCAGTTGATCGCATGGTC-3’ and B. longum 
(reverse) 5’-GGGAAGCCGTATCTCTACGA-3’ (Eurofin, 
Vimodrone, Italy). The reaction conditions for DNA 
amplification were 94 ℃ for 5 min, 35 cycles of 
94 ℃ for 20 s, 55 ℃ for 20 s, 72 ℃ for 20 s and 
72 ℃ for 5 min. Differently, for L. rhamnosus DNA 
amplification the PCR reaction was performed using 
the following primers: L. rhamn (forward) 5’-TGCATC 
TTGATTTAATTTTG-3’ and L. rhamn (reverse) 5’-CCACT 
GCTGCCTCCCGTAGGAGT-3’ (Eurofin, Vimodrone, 
Italy). The amplification profile was an initial step of 
94 ℃ for 3 min, and then 30 cycles of 94 ℃ for 45 s, 
55 ℃ for 45 s and 72 ℃ for 1 min. 
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Table 1  Baseline characteristics of health volunteers
Subject Gender Age Weight (kg) Height (m) Body mass index (kg/m2)
Pre-prandial group
   1 Female 40 70.0 1.80 21.6
   2 Female 32 65.0 1.65 23.9
   3 Male 45 57.0 1.64 21.2
   4 Male 42 73.0 1.68 25.9
   5 Male 35 85.0 1.90 23.5
   6 Male 30 82.0 1.83 24.5
   7 Male 31 71.0 1.68 25.2
   8 Male 43 82.0 1.82 24.8
Post-prandial group
   9 Male 28 71.0 1.70 24.6
   10 Male 29 64.0 1.80 19.8
   11 Male 33 81.0 1.79 25.3
   12 Male 43 72.0 1.73 24.1
   13 Male 41 81.0 1.79 25.3
   14 Male 35 71.0 1.77 22.7
   15 Female 35 61.0 1.72 20.6
   16 Female 33 60.0 1.62 22.9
Toscano M et al . Probiotics and gut microbiota
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Bacterial changes at phylum level in the gut microbiota 
composition after the probiotic consumption and one 
month after the end of probiotic oral intake
Distribution of main bacterial phyla characterizing 
the gut microbiota of individuals enrolled in the study 
is shown in Figure 3. Firmicutes were subjected to a 
significant reduction (about 50%) after one month 
of B. longum BB536 and L. rhamnosus HN001 oral 
intake (Figure 3). Moreover, one month after the end 
of probiotic administration, a further reduction of 
Firmicutes (about 20%) was observed, together with a 
significant decrease of Proteobacteria abundance (about 
58%), if compared to samples collected before probiotic 
administration.
Bacterial changes at species level in gut microbiota 
composition after the probiotic consumption and one 
month after the end of probiotic oral intake
Significant differences at species level detected in gut 
microbiota are shown in Figure 4. Immediately after 
the probiotic administration, a significant increase of 
Blautia producta, Blautia wexlerae and Haemophilus 
ducrey load was observed, together with a reduction of 
Holdemania filiformis, Escherichia vulneris, Gemmiger 
formicilis and Streptococcus sinensis abundance (Figure 
4A). 
Interestingly, the reduction of Holdemania filiformis 
remained stable up to one month after the end of 
probiotic intake (P < 0.05) (Figure 4B). 
In addition, during the follow-up period a further 
decrease in Escherichia vulneris and Gemmiger 
formicilis load, together with a reduction of Roseburia 
faecis and Ruminococcus gnavus abundance was 
observed (Figure 4B). Differently, an opposite trend 
was highlighted for Akkermansia muciniphila which 
abundance was increased if compared to samples 
collected at the beginning of the experimental time 
course (P < 0.05) (Figure 4B).
DISCUSSION
To date, there is little evidence about the ability of 
probiotics to influence the gut microbiota composition 
and many factors can negatively influence conclusions 
drawn from different studies. The administration of 
different probiotic species or strains, the duration of 
probiotic administration, the use of monostrain or 
multistrains products and the presence of numerous 
variables related to the host’s lifestyle are all elements 
which can lead to different scientific conclusions[23].
In the present study, the timing of probiotic 
administration did not significantly influence the 
colonization ability of B. longum BB536 and L. 
rhamnosus HN001. Indeed, both probiotic strains 
were capable to colonize the intestinal environment 
independently of the pre- or post-prandial oral intake. 
Furthermore, the two probiotic strains did not influence 
the gut microbiota diversity and richness of healthy 
16S gene sequencing
DNA amplification and 16S gene sequencing were 
performed as previously described[22].
Statistical analysis
The biodiversity index (Shannon, Simpson and Chao) 
and statistical analyses were carried out using the 
R Software V.3.3.1, for Windows. Non-parametric 
Kruskal-Wallis and Mann-Whitney tests were used to 
find significant differences in α diversity and microbial 
taxa. Adjustment for multiple testing was evaluated 
with Dunn’s post-hoc test. P values below 0.05 were 
considered statistically significant.  
RESULTS
In all subjects no side effects were observed following 
the oral intake of probiotic product.
Colonization ability of B. longum BB536 and 
L. rhamnosus HN001
After one month of probiotic administration, an 
increase of B. longum load was detected in 6 of 8 
subjects belonging to the pre-prandial group (Figure 
1A). This increase was maintained 1 mo after the 
end of the probiotic consumption. In 2 individuals 
(subjects 3 and 5) the B. longum load after the 
end of the treatment was higher than that detected 
immediately after the probiotic oral intake (Figure 1A). 
In the post-prandial group, however, we observed an 
increase of B. longum abundance up to 1 mo after the 
end of the probiotic in 4 subjects (Figure 1A). Only 
in one individual (subject 13), 1 mo after the end 
of the probiotic oral intake the B. longum load was 
higher than both baseline samples and samples taken 
immediately after the probiotic oral intake (Figure 1A). 
Moreover, after 1 mo of probiotic administration an 
increase of L. rhamnosus load was observed in 5 of 8 
subjects belonging to the pre-prandial group (Figure 
1B). This increase was also found 1 mo after the end 
of the probiotic, although L. rhamnosus abundance 
was slightly lower than that detected immediately after 
the month of probiotic administration (Figure 1B). In 
the post-prandial administration group, L. rhamnosus 
was increased in 4 subjects up to 1 mo after the end 
of probiotic oral intake. 
Effects of B. longum BB536 and L. rhamnosus HN001 on 
gut microbiota biodiversity 
To evaluate the bacterial diversity and richness in the 
gut microbiota before and after the intake of B. longum 
BB536 and L. rhamnosus HN001 we calculated, for 
each time point, Shannon’s, Simpson’s and Chao’s 
indices reported in Figure 2. Although no significant 
differences in gut microbiota biodiversity were observed 
after B. longum BB536 and L. rhamnosus HN001 oral 
intake, a slight reduction of Chao’s index was detected 
one month after the end of probiotic administration.
Toscano M et al . Probiotics and gut microbiota
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Figure 1  Colonization ability of Bifidobacterium longum BB536 (A) and Lactobacillus rhamnosus HN001 (B). Bar graphs represent the abundance of each 
bacterial strain, expressed as colony-forming unit per gram of feces (CFU/g feces), recovered from each subject belonging to the pre-prandial group and post-prandial 
group.
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individuals, as no significant changes in the Shannon, 
Simpson and Chao indices were detected. However, 
the Chao index was slightly decreased one month after 
the end of probiotic oral intake, suggesting a certain 
degree of uniformity between the gut microbiota of 
different subjects analyzed. These results confirmed 
data of a previous work which highlighted no significant 
effects of probiotics on the gut microbiota diversity 
and richness[23]. The lack of activity of certain probiotic 
strains on the gut microbiota could be related to their 
inability to colonize the intestinal environment. The 
ability to adhere to and colonize the gut, indeed, is a 
fundamental feature for probiotic microorganisms to be 
effective on the host and is closely species- and strain-
dependent [24]. We assume that B. longum BB536 and 
L. rhamnosus HN001 had a good colonization ability: an 
increase in B. longum and L. rhamnosus fecal load was 
detected in the majority of subjects analyzed after the 
probiotic supplementation. They also had an impact on 
the gut microbiota composition at phylum level; indeed, 
a significant reduction of Firmicutes was detected after 
one month of probiotic oral intake. This result may be 
of importance since a high abundance of Firmicutes has 
previously been related to obesity, and with a reduction 
of Bacteroidetes[25], as obese individuals often show 
an unbalanced ratio of Firmicutes and Bacteroidetes in 
their intestinal microbiota. Researchers hypothesized 
that the Firmicutes phylum contains numerous bacterial 
species with an increased ability to harvest energy from 
diet, leading to a large increase in total body fat[25]. 
Interestingly, the further reduction of Firmicutes we 
observed after the end of probiotic administration was 
concomitant to a significant reduction of Proteobacteria, 
a bacterial phylum often involved in the onset and 
progression of gastrointestinal diseases[25]. In particular, 
different microorganisms belonging to Proteobacteria, 
such as Campylobacter, enterohepatic Helicobacter 
and Escherichia coli are often associated with the 
pathogenesis of inflammatory bowel disease (IBD), 
being able to negatively influence the immune system 
and enhance intestinal inflammation[26]. Consequently, 
these changes can be considered positive marks 
due to B. longum BB536 and L. rhamnosus HN001, 
which seem to be acting as beneficial biomodulators 
of gut microbiota. Changes observed at phylum level 
were then confirmed by analyzing the distribution of 
intestinal bacterial species after probiotic oral intake; 
indeed, the Escherichia vulneris, Gemmiger formicilis 
and Ruminococcus gnavus load was reduced after 
probiotic administration. These microorganisms have 
numerous mechanisms, including secretion of toxins 
and colonization factors, for inducing the imbalance 
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of intestinal homeostasis and leading to the the 
onset of gastrointestinal diseases[27-29]. In particular, 
Ruminococcus gnavus may possess different pathogenic 
traits and virulence factors, as it was already observed 
being involved in two cases of bacteremia associated 
with diverticular disease[29]. Similarly, Gemmiger 
formicilis, together with Ruminococcus lactaris and 
Enterococcus durans, has been observed to be sig-
nificantly increased in individuals with Chron’s disease 
and subjected to recurrence of inflammatory lesions[30]. 
Probably, these bacteria can act as pro-inflammatory 
modulators enhancing the inflammatory state and 
worsening symptomatology associated to the disease. 
Interestingly, the anti-inflammatory effect B. longum 
and L. rhamnosus strains was further highlighted by 
the greater abundance of Blautia producta and Blautia 
wexlerae during the follow-up period if compared 
to samples collected at the beginning of the study 
and after one month of probiotic administration. 
Blautia spp, indeed, produce short-chain fatty acids, 
which act as main fuel for enterocytes, and anti-
inflammatory compounds involved in the promotion 
of muscular activity and epithelial cell proliferation 
and in the enhancement of blood through the colonic 
vasculature[31,32]. Moreover, several studies have already 
demonstrated the ability of both B. longum BB536 and 
L. rhamnosus HN001 to decrease the severity of allergic 
responses and positively stimulate a host’s immune 
system[20,33]. The latter, in particular, could be mediated 
by both a direct interaction between probiotic strains 
and cells of the immune system, and modulation of 
intestinal microorganisms able to influence pro- and 
anti-inflammatory response. Considering this, the 
regulation of gut microbiota composition by probiotic 
bacteria takes on an even more important role in 
maintaining a host’s health. Intestinal microbiota, 
indeed, participating in the regulation of the immune 
system, is closely involved in the onset or manifestation 
of allergic diseases, such as atopic dermatitis[34]. 
A dysbiotic microbiota can enhance intestinal and 
cutaneous pro-inflammatory response by production 
of metabolites and toxins with a strong inflammatory 
power[34]. Intestinal Staphylococcus aureus, for 
instance, which was observed to be more abundant in 
patients affected by moderate/severe atopic dermatitis, 
is able to produce a toxin with superantigenic properties 
that exacerbates atopic symptomatology[35].
More interestingly, the beneficial impact that B. 
longum and L. rhamnosus strains had on intestinal 
homeostasis is underlined by the significant increase of 
Akkermansia muciniphila detectable only after the end 
of probiotic intake. A. muciniphila is closely related with 
human health and it is inversely associated with body 
fat mass and glucose intolerance[36]. Moreover, this 
bacterium seems to be involved in the maintenance of 
intestinal barrier functions and above all in prevention 
of intestinal inflammation, playing a pivotal role in 
the host’s overall health status[37]. Also the persisting 
reduction of Streptococcus sinensis one month after 
the probiotic supplementation can be considered a 
positive mark for probiotic supplementation, as S. 
sinensis is a potential pathogenic microorganism which 
could be directly involved in infective endocarditis[38]. 
Consequently, its decrease can further underline 
the beneficial impact that B. longum BB536 and L. 
rhamnosus HN001 administration may have on gut 
microbiota of healthy individuals. 
In conclusion, our preliminary data highlighted the 
probiotic activity exerted by a B. longum BB536 and L. 
rhamnosus HN001 combination which influences the 
intestinal environment. The two probiotic strains have 
been demonstrated to influence the gut microbiota 
composition, even if all bacterial changes detected after 
probiotic intake have not yet been well-characterized. 
However, a reduction of potential harmful bacteria 
and an increase of beneficial ones may constitute an 
important probiotic feature of B. longum BB536 and 
L. rhamnosus HN001. Of course, we need further 
clinical and pre-clinical studies to demonstrate a clear 
application of this probiotics combination in the clinical 
field. 
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Figure 4  Significant changes in the gut bacterial species composition: 
(A) bacterial distribution after 1 mo of probiotic oral intake; (B) bacterial 
distribution one month after the end of probiotic (follow up) (P < 0.05).
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COMMENTS
Background
Probiotics are live microorganisms able to influence positively host’s health. 
Today, probiotic bacteria are used to improve and even prevent some human 
illnesses, such as allergic and gastrointestinal diseases, as they are able not 
only to inhibit pathogens proliferation but also to stimulate and strengthen 
host’s immune system. In the present study, Lactobacillus rhamnosus HN001 
and Bifidobacterium longum BB536 were evaluated for their ability to colonize 
intestinal environment and modify gut microbiota composition. 
Research frontiers
In probiotic research there is a high demand for studies to show mechanisms by 
which probiotic bacteria are able to influence host’s health. In particular, there is 
a great interest in understanding how probiotic can modify intestinal microbiota 
composition.
Innovations and breakthroughs
The present study was conducted with high quality and highlighted the positive 
impact of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 
on intestinal microbiota, as numerous pathogenic microorganisms were 
subjected to a significant reduction after probiotic oral intake, while the amount 
of some beneficial bacteria was observed to be increased up to the end of 
probiotic administration. 
Applications
Probiotics, and in particular Lactobacillus rhamnosus HN001 and Bifidobacterium 
longum BB536, have been demonstrated to influence positively host’s gut 
microbiota. Consequently, their use may represent a valid help in improving 
human health and reducing disease-associated symptomatology. 
Peer-review
This is a well-written paper to assess the ability of Lactobacillus rhamnosus 
HN001 and Bifidobacterium longum BB536 to colonize the gut of healthy 
subjects and to modify intestinal microbiota composition. This paper has 
potentially important implications.
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